Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vor Biopharma Inc.NASDAQ: VOR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $17.6M fell 34.1% year over year, behind the +226.5% change in trailing-twelve-month research & development. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at +70.8% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.1% toward the trailing-twelve-month pace of +226.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 321.53M USD
- Year-over-year change
- +244.6%
- 4-year CAGR
- +61.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 321.53M | +244.6% |
| FY2024 | 2024-12-31 | 93.31M | -1.1% |
| FY2023 | 2023-12-31 | 94.32M | +46.1% |
| FY2022 | 2022-12-31 | 64.55M | +35.8% |
| FY2021 | 2021-12-31 | 47.53M | — |
Research & Development vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 research & development of $312.43M is the 2nd highest of the 10 companies compared; the peer median is $112.11M.
- Its year-over-year change of +226.5% is the highest of 10, against a peer median of -21.5%.
- Over three fiscal years its annual growth of +70.8% compares with a peer median of -5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $312.43M | +226.5% | +70.8% | — | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $146.28M | -4.6% | -13.1% | — | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $88.91M | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| Peer median (excluding VOR) | $112.11M | -21.5% | -5.0% | 546.5% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 8.96M | 3.49M | 0 | 0 |
| Gross Profit | 0 | (8.96M) | (3.49M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.53M | 64.55M | 94.32M | 93.31M | 321.53M |
| Selling, General & Admin | 21.49M | 19.91M | 31.72M | 27.88M | 50.11M |
| Operating Expenses | 69.02M | 84.46M | 122.54M | 121.19M | 371.64M |
| Depreciation & Amortization | 1.43M | 8.96M | 3.49M | 3.53M | 2.89M |
| EBITDA | (67.47M) | (83.13M) | (114.37M) | (113.39M) | (693.09M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (69.02M) | (93.42M) | (126.04M) | (121.19M) | (371.64M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 119K | 1.32M | 8.17M | 4.27M | 5.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 119K | 1.32M | 8.17M | 4.27M | (324.34M) |
| Income Before Tax | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| EPS (Diluted) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| Weighted Avg Shares | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
| Weighted Avg Shares (Diluted) | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.